Jia-ying Zhou
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.
Journal: Experimental hematology & oncology
Published: September 18, 2021
Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score.
Journal: Translational oncology
Published: August 01, 2021
Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy.
Journal: Frontiers in oncology
Published: July 27, 2020
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.
Journal: Expert opinion on drug safety
Published: April 09, 2020
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Journal: EBioMedicine
Published: March 30, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism.
Journal: Clinical and translational medicine
Published: February 23, 2020
Association between APOBEC3H-Mediated Demethylation and Immune Landscape in Head and Neck Squamous Carcinoma.
Journal: BioMed research international
Published: January 31, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026